- Home
- AMIX vs RDHL Comparison
AMIX vs RDHL Comparison
Compare AMIX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- RDHL
- Stock Information
- Founded
- AMIX 2014
- RDHL 2009
- Country
- AMIX United States
- RDHL Israel
- Employees
- AMIX N/A
- RDHL N/A
- Industry
- AMIX
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- RDHL Health Care
- Exchange
- AMIX NYSE
- RDHL Nasdaq
- Market Cap
- AMIX 7.3M
- RDHL 8.6M
- IPO Year
- AMIX N/A
- RDHL N/A
- Fundamental
- Price
- AMIX $3.46
- RDHL $6.38
- Analyst Decision
- AMIX
- RDHL
- Analyst Count
- AMIX 0
- RDHL 0
- Target Price
- AMIX N/A
- RDHL N/A
- AVG Volume (30 Days)
- AMIX 188.6K
- RDHL 21.6K
- Earning Date
- AMIX 02-11-2025
- RDHL 01-03-2025
- Dividend Yield
- AMIX N/A
- RDHL N/A
- EPS Growth
- AMIX N/A
- RDHL N/A
- EPS
- AMIX N/A
- RDHL N/A
- Revenue
- AMIX N/A
- RDHL $3,707,000.00
- Revenue This Year
- AMIX N/A
- RDHL $224.90
- Revenue Next Year
- AMIX N/A
- RDHL $82.69
- P/E Ratio
- AMIX N/A
- RDHL N/A
- Revenue Growth
- AMIX N/A
- RDHL N/A
- 52 Week Low
- AMIX $2.88
- RDHL $6.00
- 52 Week High
- AMIX $152.00
- RDHL $40.50
- Technical
- Relative Strength Index (RSI)
- AMIX 34.39
- RDHL 40.01
- Support Level
- AMIX $2.88
- RDHL $6.00
- Resistance Level
- AMIX $3.60
- RDHL $7.30
- Average True Range (ATR)
- AMIX 0.33
- RDHL 0.45
- MACD
- AMIX 0.22
- RDHL -0.09
- Stochastic Oscillator
- AMIX 45.90
- RDHL 25.85
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.